BioCareSD, a specialty distributor of life-saving therapies, today announced that ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, is now available through their network.
TEMPE, Ariz. – April 13, 2023 – BioCareSD, a specialty distributor of life-saving therapies, today announced that ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, is now available through their network. It is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A.
Hemophilia A is a rare, lifelong condition in which the ability of a person’s blood to clot properly is impaired, leading to excessive bleeds and spontaneous bleeds into joints that can result in joint damage and chronic pain. ALTUVIIIO, developed jointly by Sanofi and Sobi, is the first and only factor VIII replacement therapy to deliver near-normal factor activity levels (>40%) for the majority of the week with once-weekly dosing, compared to standard half-life (SHL) and extended half-life (EHL) products requiring multiple infusions each week.
“We are proud to launch distribution of ALTUVIIIO in order to help improve the lives of those living with hemophilia A,” said Jeff Beck, BioCareSD’s Chief Development Officer. “It is just one of several vital pharmaceuticals we will add this year as we continue to expand and diversify our product portfolio.”
In February of this year, ALTUVIIIO was approved by the U.S. Food and Drug Administration (FDA) as a factor VIII therapeutic for hemophilia A. The FDA previously granted ALTUVIIIO Breakthrough Therapy designation in May 2022 – the first factor VIII therapy to receive this recognition – Fast Track designation in February 2021, and Orphan Drug designation in August 2017.
Over the last four decades, BioCareSD has delivered therapies to patients with ultra-rare, rare, and orphan diseases through partnership with manufacturers and healthcare providers. For more information, please visit www.biocaresd.com.
###
About BioCareSD
BioCareSD, a BioCare company, has been providing patients across the country with fast and easy access to life-saving medications for over 40 years. This is accomplished via their wide reaching nationwide network of distribution centers and agile distribution capabilities, offering both STAT and emergency deliveries. Headquartered in Tempe, Arizona, BioCareSD has a central customer support team and local, field-based account management teams, available 24 hours a day, 7 days a week, 365 days a year. For more information, please visit www.biocaresd.com.